ADVERTISING GROUP OF THE DIRECTORATE OF MEDICINES - CPSP 435 TO 438 OF 2026

The National Institute for Food and Drug Surveillance (INVIMA) is seeking specialized professional services for its Advertising Group within the Directorate of Medicines and Biological Products. The contracts, CPSP 435 to 438 of 2026, involve supporting the review and analysis of advertisements for post-marketed medicines, homeopathic medicines, and phytotherapeutic products. This review is conducted under the framework of prior and subsequent control, which is INVIMA's responsibility. The duration for each contract is 300 days, and they will be awarded through direct contracting. The objective is to ensure that all advertising for pharmaceutical and related products complies with regulatory standards, protecting public health by preventing misleading or unsubstantiated claims. The professionals will provide expert analysis of advertising materials, verifying their accuracy and adherence to legal requirements, thereby supporting INVIMA's regulatory oversight function.

This is a services contract in the media and communication, health and medical services and general supplies sectors. Located in Colombia, Latin America, this opportunity is open to firms and consortiums, with an estimated budget of COP 59.5 million.

Published through SECOP II Colombia (Date-Filtered), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for services in the media and communication sector. Service contracts are typically evaluated on both technical quality and price, and may require bidders to demonstrate relevant experience and qualified personnel. This contract has already been awarded. The information is published for transparency and market intelligence purposes.